Gusperimus

Drug Profile

Gusperimus

Alternative Names: 15-Deoxyspergualin; BMS 181173; BMY 422151; Deoxyspergualin; Deoxyspurgiline; DSG; Heptanamide; NKT 301; NKT-01; NSC 356894; Spandin injection; Spandin®; Spanidin; Spanidin injection

Latest Information Update: 03 Jun 2015

Price : $50

At a glance

  • Originator Institute of Microbial Chemistry
  • Developer Nippon Kayaku; Nordic Group
  • Class Cytostatic antibiotics; Guanidines; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Wegener's granulomatosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal transplant rejection
  • Phase III Wegener's granulomatosis
  • Discontinued Cancer; Diabetes mellitus; Glomerulonephritis; Hypersensitivity; Immunological disorders; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 31 Mar 2014 Nordic Pharma suspends enrolment in the phase III SPARROW trial for Wegener's granulomatosis in Czech Republic, Germany, Sweden and Spain (NCT01446211)
  • 19 Jan 2012 Phase-III clinical trials in Wegener's granulomatosis (recurrent) in Germany, Sweden, Spain and United Kingdom (SC) after January 2012
  • 19 Jan 2012 Nordic Pharma initiates enrolment in a phase III trial for Wegener's granulomatosis (recurrent) in Czech Republic (NCT01446211)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top